Condition: Breast Cancer · Axillary Nodal Disease · Female Breast Cancer · Sponsor: Alice Chung
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
This description comes directly from the study's public registry record.
Clinical Trial Navigator · 3104232133 · GroupCancerTrialInformation@cshs.org
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles, California, United States | Recruiting |
| CS Cancer at Huntington Cancer Center | Pasadena, California, United States | Recruiting |
| CS Cancer at Valley Oncology Medical Group | Tarzana, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06092892